In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus .

Autor: Chen L; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA., Shashkina E; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Kurepina N; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Calado Nogueira de Moura V; Department of Medicine, National Jewish Health, Denver, Colorado, USA.; The University of Colorado, Aurora, Colorado, USA., Daley CL; Department of Medicine, National Jewish Health, Denver, Colorado, USA.; The University of Colorado, Aurora, Colorado, USA., Kreiswirth BN; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 May 02; Vol. 68 (5), pp. e0017424. Date of Electronic Publication: 2024 Apr 01.

Ecological and economic security as a factor of sustainable rural development

Autor: Kurepina N L, Berikova N B, Shovaeva M V, Mandzhieva D V

Publikováno v: E3S Web of Conferences, Vol 161, p 01007 (2020)

Today, in the 21st century, our society rapidly exhausts natural resources without care for the preservation of the environment. The dependence on the environmental factor in such sectors of the economy as the agricultural one that thoroughly depends

Externí odkaz: https://doaj.org/article/81b95c1a4bdd4560a14d2a012d19e7a6

Ultrasensitive Detection of Multidrug-Resistant Mycobacterium tuberculosis Using SuperSelective Primer-Based Real-Time PCR Assays.

Autor: Narang A; Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA., Marras SAE; Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA., Kurepina N; Center for Discovery and Innovation, Nutley, NJ 07110, USA., Chauhan V; Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110021, India., Shashkina E; Center for Discovery and Innovation, Nutley, NJ 07110, USA., Kreiswirth B; Center for Discovery and Innovation, Nutley, NJ 07110, USA., Varma-Basil M; Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110021, India., Vinnard C; New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA., Subbian S; Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Dec 12; Vol. 23 (24). Date of Electronic Publication: 2022 Dec 12.

A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-Resistant Neisseria gonorrhoeae and Other High-Threat Pathogens.

Autor: Park S; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Russo R; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA., Westfall L; Southern Research, Infectious Disease Research, Birmingham, Alabama, USA., Shrestha R; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA., Zimmerman M; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Dartois V; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Kurepina N; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Kreiswirth B; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Singleton E; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA., Li SG; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA., Mittal N; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA., Ahn YM; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA., Bilotta J; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA., Connolly KL; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciencesgrid.265436.0, Bethesda, Maryland, USA., Jerse AE; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciencesgrid.265436.0, Bethesda, Maryland, USA., Freundlich JS; Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jerseygrid.430387.b, Newark, New Jersey, USA.; Department of Pharmacology and Physiology, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA., Perlin DS; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Sep 20; Vol. 66 (9), pp. e0041422. Date of Electronic Publication: 2022 Aug 16.

CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on β-Lactam Susceptibility.

Autor: Kurepina N; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Chen L; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA., Composto K; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Rifat D; The Center for Tuberculosis Research, Department of Medicine, Johns Hopkins Universitygrid.21107.35, Baltimore, Maryland, USA., Nuermberger EL; The Center for Tuberculosis Research, Department of Medicine, Johns Hopkins Universitygrid.21107.35, Baltimore, Maryland, USA., Kreiswirth BN; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Apr 19; Vol. 66 (4), pp. e0009322. Date of Electronic Publication: 2022 Mar 21.